Alto Neuroscience ANRO Change in Accrued Liabilities
Change in Accrued Liabilities at other companies
Other financials
Where this comes from
Reported directly by Alto Neuroscience in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities.
The official record: Alto Neuroscience’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Alto Neuroscience's change in accrued liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Alto Neuroscience's change in accrued liabilities?
- Alto Neuroscience (ANRO) reported change in accrued liabilities of -$1.75M in Q1 2026.
- How has Alto Neuroscience's change in accrued liabilities changed year-over-year?
- Alto Neuroscience's change in accrued liabilities increased by 35.1% year-over-year, from -$2.7M to -$1.75M.
- What does change in accrued liabilities mean?
- Change in accrued expenses and other current liabilities, reflecting timing differences between expense recognition and cash payment.